Table 4.
Change in individual hemostasis parameters and in clot lysis time, stratified by use of tamoxifen and AIs
| Tamoxifen (n=42) | Aromatase inhibitors (n=65) | |||||||
|---|---|---|---|---|---|---|---|---|
| T1 mean (SD) | T2 mean (SD) | Absolute difference (95% CI) | P | T1 mean (SD) | T2 mean (SD) | Absolute difference (95% CI) | P | |
| PT, % | 95.8 (6.2) | 95.9 (7.2) | 0 (−1.5 to 1.6) | .98 | 96.8 (6.0) | 96.7 (6.1) | 0 (−1.2 to 1.0) | .89 |
| aPTT, s | 28.4 (2.6) | 26.0 (2.4) | −2.5 (−3.2 to−1.8) | <.001* | 28.8 (3.7) | 28.2 (4.0) | −0.6 (−1.2 to −0.1) | .033 |
| Fibrinogen, g/L | 3.2 (0.6) | 2.5 (0.4) | −0.7 (−0.9 to−0.5) | <.001* | 3.6 (0.7) | 3.4 (0.7) | −0.1 (−0.3 to 0.0) | .096 |
| D-dimer, ng/mL | 446.2 (423.8) | 292.4 (137.7) | −153.7 (−285.2 to−22.3) | .023 | 710.6 (642.8) | 560.6 (282.2) | −150.0 (−309.2 to 9.2) | .064 |
| FII, % | 103.5 (17.8) | 97.3 (17.9) | −6.2 (−10.8 to−1.7) | .008 | 109.0 (20.4) | 109.9 (17.4) | −0.8 (−5.0 to 3.3) | .7 |
| FVII, % | 95.4 (21.4) | 93.1 (21.7) | −2.2 (−5.98 to 1.4) | .22 | 105.1 (27.0) | 103.8 (24.7) | −1.3 (−5.3 to 2.7) | .52 |
| FVIII, % | 135.2 (42.0) | 138.3 (44.7) | +3.0 (−3.5 to 9.6) | .36 | 152.3 (38.3) | 152.8 (42.5) | +0.5 (−5.7 to 6.6) | .88 |
| AT, % | 96.0 (9.5) | 88.0 (10.8) | −8.1 (−10.8 to−5.5) | <.001* | 98.4 (12.9) | 100.2 (12.4) | +1.8 (−0.5 to 4.1) | .12 |
| Free protein S, % | 83.0 (10.2) | 91.1 (12.4) | +8.1 (5.1−11.1) | <.001* | 91.2 (13.8) | 93.6 (11.9) | +2.4 (0.5 to 4.3) | .017 |
| Protein C, % | 105.0 (23.8) | 98.8 (21.2) | −6.2 (−10.6 to−1.9) | .006 | 113.8 (23.0) | 113.5 (22.1) | −0.3 (−3.6 to 3.0) | .85 |
| TFPI, pg/mL | 365.0 (96.0) | 315.7 (85.8) | −49.2 (−69.0 to−29.5) | <.001* | 507.0 (137.5) | 510.8 (135.2) | +3.7 (−21.8 to 29.3) | .77 |
| Clot lysis time, s | 909.3 (194.4) | 839.0 (172.4) | −70.3 (−121.3 to−19.3) | .008 | 975 (201.9) | 1024.8 (385.4) | +48.9 (−49.7 to 147.5) | .33 |
AT, antithrombin; CTL, clot lysis time.
*
Statistically significant with a Bonferroni-corrected α threshold of <.0016.